Search results for : e2 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Search Results for: e2

Drugs (5)
Celllines ( 4)
Genetic Features (1)

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
Cabozantinib	BMS-907351, XL-184, Cometriq	VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, TIE2,AXL	RTK signaling	25102847	GDSC1	911	MGH
Foretinib	GSK1363089, XL-880, EXEL-2880, GSK089	MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, EGFR	RTK signaling	42642645	GDSC1	909	MGH
Foretinib	GSK1363089, XL-880, EXEL-2880, GSK089	MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, EGFR	RTK signaling	42642645	GDSC2	953	SANGER
Kobe2602		RAS effector	RTK signaling		GDSC1	907	MGH
Ponatinib	AP24534, AP-24534, KIN001-192, Iclusig	ABL, PDGFRA, VEGFR2, FGFR1, SRC, TIE2, FLT3	Other, kinases	24826799	GDSC1	877	MGH

Name	Cell Model Passport Link	COSMIC ID	Tissue	Tissue sub-type
BE2-M17	SIDM01229	753616	NB	Nervous system
BE2-M17	SIDM01229	753616	NB	Nervous system
OE21	SIDM00478	1298359	ESCA	Aero digestive tract
OE21	SIDM00478	1298359	ESCA	Aero digestive tract

Feature Name	Feature Type
NFE2L2_mut	coding variant

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).